DEF: Rezolute to Increase Equity Incentive Plan Shares

Rezolute, Inc. schedules its 2026 Annual Meeting of Stockholders for November 19, 2025, to vote on key proposals including director elections and an amendment to the equity incentive plan.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on November 19, 2025, at 3:00 p.m. Pacific Time.
• Stockholders of record as of September 22, 2025, are entitled to vote.
• The board recommends voting FOR all director nominees, the ratification of Grant Thornton LLP, the Say-On-Pay proposal, the 2021 Equity Plan Amendment Proposal, and the Adjournment Proposal.
• A proposal to amend the 2021 Equity Incentive Plan to increase the number of shares available for issuance from 14,450,000 to 21,950,000 will be voted on.
• The company has seven directors serving on the board, all of whom have been nominated for re-election.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing is a standard proxy statement outlining routine corporate governance matters. The proposals are generally aimed at ensuring the company can continue to operate effectively.

Positives

• The Board of Directors recommends stockholders vote FOR the election of each of the director nominees.
• The Board of Directors recommends stockholders vote FOR the ratification of Grant Thornton as the company's independent registered public accounting firm.
• The Board of Directors recommends stockholders vote FOR the proposal to approve the compensation of the named executive officers.
• The Board of Directors recommends stockholders vote FOR the 2021 Equity Plan Amendment.
• The Board of Directors recommends stockholders vote FOR the Adjournment Proposal.

Negatives

• The company's net income for fiscal year 2025 was negative, at $(74,412,000).
• Nevan Charles Elam, Chief Executive Officer and Acting Chairman of the Board, is not independent as defined in Section 5605(a) of Nasdaq listing rules.
• Young-Jin Kim is not independent as defined in Section 5605(a) of Nasdaq listing rules.

Risks

• If any director-nominee should withdraw or otherwise become unavailable for reasons not presently known, the proxies which would have otherwise been voted for that director nominee may be voted for a substitute director nominee selected by our Board.
• The company's compensation recovery policy (the Clawback Policy) provides for the recovery of certain incentive-based compensation paid or granted to our executive officers in the event we are required to restate our financial statements.
• Section 162(m) of the Code prohibits publicly held corporations from deducting more than $1 million per year in compensation paid to certain named executive officers.

Future Outlook

The filing includes forward-looking statements related to the election of directors and the ratification of the accounting firm for the fiscal year ending June 30, 2026. The company also seeks to increase the number of shares available for issuance under the 2021 Equity Incentive Plan.

Management Comments

• Nevan Charles Elam, Chief Executive Officer and Acting Chairman of the Board: By order of the Board of Directors.
• The Board believes that combining the Chairman and Chief Executive Officer positions are currently the most effective leadership structure for the Company given Mr. Elams in-depth knowledge of the Companys business, operations and industry, as well as his ability to formulate and implement strategic initiatives.

Industry Context

Rezolute, Inc. is operating in the biopharmaceutical industry, which is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The proposals in this proxy statement, particularly the equity incentive plan amendment, are common mechanisms used by companies in this sector to attract and retain talent.

Comparison to Industry Standards

• Director compensation: The director compensation structure, including cash and share-based incentives, is generally in line with industry standards for small to mid-sized biopharmaceutical companies.
• Equity Incentive Plans: Increasing the number of shares available under equity incentive plans is a common practice in the biotech industry to attract and retain employees and align their interests with those of shareholders. Companies like Ultragenyx Pharmaceutical Inc. also use equity compensation extensively.
• Auditor Ratification: Ratifying the appointment of an independent auditor is a standard corporate governance practice. Grant Thornton LLP is a well-recognized accounting firm, similar in stature to BDO or RSM, which are often used by comparable companies.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings involving directors, executive officers, promoters, or control persons are disclosed.

Related Party Transactions

• In connection with the 2024 Private Placement in July 2024, Handok purchased 1,250,000 shares of common stock at $4.00 per share.
• In connection with the 2025 Private Placement in May 2025, Handok and Nerissa Kreher purchased 1,230,769 and 3,076 shares, respectively, of common stock at $3.25 per share.

Stakeholder Impact

• Shareholders: The proposals directly impact shareholders through potential dilution (equity plan amendment) and corporate governance practices.
• Employees: The equity incentive plan is designed to attract, retain, and motivate employees.
• Customers: No direct impact on customers is mentioned in the filing.
• Creditors: No direct impact on creditors is mentioned in the filing.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• The company to hold the 2026 Annual Meeting of Stockholders on November 19, 2025.
• The Board of Directors to implement the outcomes of the votes.

Key Dates

Recommendation

The company is asking for more shares to be issued under the equity incentive plan, which is a common practice in the biotech industry to attract and retain employees and align their interests with those of shareholders. However, the company's net income for fiscal year 2025 was negative, at $(74,412,000). Therefore, a hold recommendation is appropriate.

Keywords

proxy statement, annual meeting, Rezolute, directors, executive compensation, equity incentive plan, Grant Thornton